Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity

What is the effect of ixekizumab plus tirzepatide on disease activity and weight in adults with psoriasis and overweight or obesity?In this randomized clinical trial of 274 participants, 27.1% receiving ixekizumab plus tirzepatide vs 5.8% receiving ixekizumab alone simultaneously achieved Psoriasis Area Severity Index (PASI) 100 and 10% or greater weight reduction; 40.6% vs 29.0% achieved PASI 100 at week 36, respectively. Treatment differences were significant.The trial results suggest that, in adults with difficult-to-treat psoriasis due to overweight or obesity, concomitant ixekizumab and tirzepatide improved complete skin clearance (PASI 100) and reduced weight, supporting comprehensive management of obesity and psoriasis as a potential new treatment approach.

Corresponding Author: Cianna Leatherwood, MD, MPH, Eli Lilly and Company, Lilly Corporate Center, DC 5027, Indianapolis, IN 46285 (cianna.leatherwood@lilly.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.